Kazia Therapeutics Limited (KZIA) - Long-Term Liabilities to Capital

Kazia Therapeutics (KZIA) is an Australian developer of brain tumor therapies focused on clinics and the precision medicine segment via paxilisib. This chart's price trend complements data on long-term liabilities, which amount to 0.00. Orphan drug status guarantees a lack of competitors and premium pricing, yet the company remains in a liquidity deficit due to global testing costs.

To select high-quality assets, an investor must evaluate the stability of a company's financial leverage. This ratio compares liabilities with maturities exceeding one year to total equity, measuring the degree of debt load. For Kazia Therapeutics (KZIA), which is developing innovative drugs against glioblastoma, this is critical when financing clinical trials. Analyzing the long-term capital structure indicator allows for the determination of bankruptcy risk. The price action on this chart confirms a balance between borrowed funds and equity.